北京时间5月15日收盘,KROS市盈率为-44.49,KROS市值为5亿美元

KROS简介

KerosTherapeutics,Inc.isaclinical-stagebiopharmaceuticalcompanyfocusedonthediscovery,developmentandcommercializationofnoveltreatmentsforpatientssufferingfromhematologicalandmusculoskeletaldisorderswithhighunmetmedicalneed.ItisaleaderinunderstandingtheroleoftheTransformingGrowthFactor-Beta,orTGF-Beta,familyofproteins,whicharemasterregulatorsofredbloodcellandplateletproductionaswellasofthegrowth,repairandmaintenanceofmuscleandbone.Ithasleveragedthisunderstandinganddevelopedadiscoveryapproachtogeneratelargeandsmallmoleculestoaddressdiseasesofthesetissues.TargetingTGF-Betasignalingpathwayshasbeenclinicallyproventoelicitrobustchangesinbloodcells,muscleandbone,whichitbelieveprovidesaprecedentandstrongrationaleforitsstrategy.Itsleadproteintherapeuticproductcandidate,KER-050,isbeingdevelopedforthetreatmentoflowbloodcellcounts,orcytopenias,includinganemiaandthrombocytopenia,inpatientswithmyelodysplasticsyndromes,orMDS,andinpatientswithmyelofibrosis.IthasobservedpositivetoplineresultsinaPhase1clinicaltrialofKER-050,anditplantoinitiatetwoPhase2clinicaltrials,oneinpatientswithMDSandoneinpatientswithmyelofibrosis.Itsleadsmallmoleculeproductcandidate,KER-047,isbeingdevelopedforthetreatmentofanemiaresultingfromelevatedlevelsofhepcidin,thekeyregulatorofironabsorptionandrecycling,aswellasforthetreatmentoffibrodysplasiaossificansprogressiva,orFOP,araremusculoskeletaldisorder,andiscurrentlyinaPhase1clinicaltrial.Itsthirdproductcandidate,KER-012,isbeingdevelopedforthetreatmentofdisordersassociatedwithboneloss,suchasosteoporosisandosteogenesisimperfecta,andforthetreatmentofpulmonaryarterialhypertension,orPAH.ItplantoprogressKER-012intoaPhase1clinicaltrialinthesecondhalfof2021.